Worldwide Clinical Trials Experts To Advance Dialogue On The Future Of Clinical Research For Immune-Mediated Inflammatory Disorders

MORRISVILLE, N.C.--(BUSINESS WIRE)--To advance exploration of uncommon approaches to clinical research and development challenges, Worldwide Clinical Trials (www.worldwide.com) will host the next in its series of ‘Eavesdropping on the Experts’ webinars, titled “Exploring the Future of Clinical Research for Immune-Mediated Inflammatory Disorders.”

“Exploring the Future of Clinical Research for Immune-Mediated Inflammatory Disorders”

Significant research into immune-mediated inflammatory disorder (IMID) pathology and genetic links has led to the knowledge that underpinning these diseases is the dysregulation of the immune system, which leads to widespread and chronic inflammation. These discoveries have delivered a more comprehensive understanding of immune-mediated mechanisms, and the promise for more effective treatments and possibly even cures for a range of IMID disorders. Worldwide clinical research experts in IMID will address the challenges sponsors and contract research organizations (CROs) face when designing clinical development plans for therapeutic targets with unsettled trial methodology, selecting optimal outcomes given the importance of patient reported outcomes, and encountering barriers during the execution of international clinical trials for promising new compounds within this therapeutic area.

• WHAT: Complimentary, Live Webinar: “Exploring the Future of Clinical Research for Immune-Mediated Inflammatory Disorders”
• WHEN: 11am ET on Thursday, August 31, 2017
• WHERE: Reserve your spot today. Register Online Here

• WHO: WORLDWIDE CLINICAL TRIALS EXPERTS:

  • Host: Michael F. Murphy, M.D., Ph.D., Chief Medical and Scientific Officer
  • Rolana Avrumson, M.S., Associate Director of Clinical Projects, Clinical Assessment Technologies
  • Jim Khalifa, M.D., Executive Medical Director, IMID Medical Lead, Medical and Scientific Affairs
  • William Slone, Ph.D., Fellow, Clinical Research Methodology
  • Eteri Tsetskhladze M.D. Ph.D., Senior Medical Director, Medical and Scientific Affairs
  • Ingrid Vanrompaey, Ph.D., Director, Project Management

Drawing on a wealth of knowledge and experience gleaned by running hundreds of clinical trials in pursuit of treatments for IMID indications, the Worldwide expert panel will discuss factors critical to the success of IMID drug development, including:

• Considerations when conducting global research, spurred by the prospect of lower costs, less competition for investigator sites, and the search for treatment-naïve patients or those with unique treatment trajectories and pedigrees
• The challenge of standardized protocols when clinical trial protocols are not consistent with clinical practice, making it difficult for investigators to comply, and options for exploring adaptive clinical trial design to align with advancements in the clinical management of a disease and its course
• Innovative measures and methods of data acquisition for the assessment of outcomes relevant to patients
• Uncommon approaches for patient recruitment when faced with complex protocols, competition with a wide range of currently-available treatments and a limited supply of investigator sites and willing patients

This session is the latest in Worldwide’s ongoing, complimentary webinar series. To access on-demand versions of past webinars, visit www.worldwide.com/webinars, or for further information about Worldwide Clinical Trials, please visit Worldwide.com.

Connect with Worldwide Clinical Trials:

• Tweet: @Worldwidetrials to host free webinar exploring #ClinicalResearch for #IMIDs - Reserve your spot today! http://bit.ly/2vfZ3rS
• Follow us on Twitter: @worldwidetrials
• Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From Early Phase and Bioanalytical Sciences through Late Phase and post approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit Worldwide.com.